BioCardia

Q2 FY2026 EarningsQ2 FY26 results beat consensus on earnings while remaining in a pre-revenue stage. Net loss of -$1.61M was narrower than the expected -$2.15M, and GAAP EPS of -$0.13 beat the -$0.18 estimate. The variance was primarily driven by lower-than-anticipated R&D spending following the closeout of the CardiAMP HF Trial. However, liquidity remains critical as the $4.1M cash balance is projected to fund operations only through January 2027, necessitating further capital raises.